A comparison of efficacy between recombinant activated factor vii (aryoseven tm) and Novoseven® in patients with hereditary FVIII deficiency with inhibitor

Authors
Category Primary study
JournalBlood
Year 2014
This article has no abstract
Epistemonikos ID: 33ba668ff3565300da0d6665b6b44d0f47ed0d1e
First added on: Feb 06, 2025